Status: Recruiting
A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to assess preliminary efficacy, determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Adze Biotechnology Australia Pty LtdUpdated: Jul 8, 2026Locations: 3
Eligibility criteria
Male or female participants aged 18 years or older at Screening. [+8]
Active systemic infection or fever ≥ 38°C within 5 days prior to Screening [+15]